M&A Deal Summary |
|
|---|---|
| Date | 2024-02-01 |
| Target | Biovian |
| Sector | Life Science |
| Buyer(s) | 3PBiovian |
| Sellers(s) | Keensight Capital |
| Deal Type | Merger |
SEARCH BY
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. 3PBiovian's service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adenoassociated viruses, cell therapy, and plasmid DNA production. Additionally, 3PBiovian provide fill and finish services for recombinant proteins and viral vectors. 3PBiovian is based in Turku, Finland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Merger M&A Deals | 2 of 2 |
| Country: Finland M&A | 1 of 1 |
| Year: 2024 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-01 |
3P Biopharmaceuticals
Noain, Spain 3P Biopharmaceuticals is specialized in the development of biotechnological products and processes: advanced therapy molecules, vaccines and biosimilar medicines, such as proteins and monoclonal antibodies for various therapeutic indications. 3P Biopharmaceuticals was founded in 2006 and is based in Noain, Spain. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 5.5B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Keensight Capital is a private equity investment firm focused on majority and minority growth capital investments in Western European companies. Keensight makes equity investments in a number of situations including the provision of capital to finance growth, either organically or through acquisitions, or the buying out of existing shareholders. The Firm looks to invest €10 to €600 million and will consider business with up to €400 million in revenue. Keensight Capital was formed in 2000 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 24 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Merger M&A Deals | 3 of 3 |
| Country: Finland M&A | 1 of 1 |
| Year: 2024 M&A | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-01 |
3P Biopharmaceuticals
Noain, Spain 3P Biopharmaceuticals is specialized in the development of biotechnological products and processes: advanced therapy molecules, vaccines and biosimilar medicines, such as proteins and monoclonal antibodies for various therapeutic indications. 3P Biopharmaceuticals was founded in 2006 and is based in Noain, Spain. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-06 |
Plat4mation
Utrecht, Netherlands Plat4mation is a global pure-play ServiceNow Elite partner. The Company helps ServiceNow customers across the entire value chain, offering a comprehensive suite of advisory, implementation, and managed services solutions. Plat4mation was founded in 2013 and is based in Utrecht, Netherlands. |
Buy | - |
